precision medicine

Research in Review

Blinatumomab Induces Complete Remission in Children with BCP-ALL

10/07/2016

JCP Editors

Results from a phase I/II single-arm trial suggest that blinatumomab may have an antileukemic effect in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). ALL is a progressive...

...

10/07/2016

Journal of Clinical Pathways

Department

Hypofractionated Radiation Therapy Offers Value-Based Care for Patients With Prostate Cancer

10/04/2016

JCP Editors

In the first study to evaluate patient-reported outcomes from the NRG Oncology/RTOG 0415 trial, treatment with hypofractionated radiation therapy offers similar health-related quality of life (HRQoL) outcomes in...

In the...

10/04/2016

Journal of Clinical Pathways

Research in Review

Non-TNF Agents Show Promise for Patients With Inadequate RA Response

09/30/2016

JCP Editors

Patients with rheumatoid arthritis (RA) previously treated to a first-line anti-tumor necrosis factor (TNF) drug who have an inadequate response may experience a better outcome with a non-TNF biologic agent than with...

...

09/30/2016

Journal of Clinical Pathways

Department

PD-L1 Tests for NSCLC Differ in Effectiveness

09/28/2016

JCP Editors

A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...

A...

09/28/2016

Journal of Clinical Pathways

Research in Review

Drug Combination Does Not Benefit Patients With Colorectal Cancer

09/26/2016

JCP Editors

There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial. Bevacizumab, along with other angiogenesis inhibitors,...

There...

09/26/2016

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitor-Related Pneumonitis Most Common in NSCLC

09/23/2016

JCP Editors

Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...

...

09/23/2016

Journal of Clinical Pathways

Research in Review

No Difference in 5-Year Survival With Lung Cancer Staging Strategies

09/21/2016

JCP Editors

New data from a post-hoc analysis of the Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial found no survival difference at 5 years with endosonography or mediastinoscopy...

New...

09/21/2016

Journal of Clinical Pathways

Department

Keynote Presentation - Precision Medicine: An Essential Component of Oncology Clinical Pathways

09/17/2016

JCP Editors

Richard Schilsky, MD, senior vice president and chief medical officer of the American Society of Clinical Oncology kicked off the inaugural Clinical Pathways Congress with a discussion on the relationship between...

...

09/17/2016

Journal of Clinical Pathways

Research in Review

Novel Tumor Analysis Method Identifies Aggressive Prostate Cancer

09/17/2016

JCP Editors

Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed. Researchers at Cedars-Sinai have developed a new method to identify which...

...

09/17/2016

Journal of Clinical Pathways

Research in Review

Evidence for Liquid Biopsy Use in Lung Cancer Grows

09/14/2016

JCP Editors

A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies, according to a study published in the journal Clinical...

A...

09/14/2016

Journal of Clinical Pathways